WASHINGTON (dpa-AFX) - Edwards Lifesciences Corp. (EW) has completed the acquisition of privately held Dutch company BMEYE B.V. The purchase price was 32.5 million euros or about $42 million. Edwards anticipates that the net earnings impact from this transaction would be immaterial in 2012, and slightly dilutive in 2013.
While BMEYE's products are chiefly used by clinicians outside of the hospital, over the next 18 months, Edwards intends to develop BMEYE's technology and integrate it into the Edwards EV1000 clinical platform for use in the acute care setting in hospitals.
The company noted that BMEYE's technology provides continuous, real-time information to clinicians and can be used in the surgical, intensive care, emergency room and cardiology settings. BMEYE's monitoring products work with a non-invasive finger cuff to measure continuous, real-time information on cardiac output, blood pressure, fluid responsiveness and other important hemodynamic parameters. Currently, BMEYE's products are approved for sale in the U.S., throughout Europe and in several other countries.
Copyright RTT News/dpa-AFX